Centivax develops broad-spectrum vaccines aimed at preventing infectious diseases across different species. Their current focus is on a universal influenza vaccine currently in pre-clinical development for ferrets and pigs. The company seeks to advance global health by creating preventative measures against widespread pathogens.

General Fluidics develops the Axess™ point-of-care testing platform, which integrates hematology, clinical chemistry, and immunoassay technologies into a single low-cost cartridge for blood diagnostics. This solution addresses the need for accessible, high-quality testing by streamlining workflows and minimizing pre-analytical errors in clinical settings.

Rejuvenate Bio utilizes gene therapy to develop treatments aimed at reversing aging and addressing chronic, age-related diseases that affect six in ten Americans. By targeting the underlying genetic factors of these conditions, the company aims to reduce the prevalence and healthcare costs associated with chronic diseases.